No Data
No Data
Chenxin Pharmaceutical (603367.SH): R&D investment in 2023 accounts for more than 8% of revenue
Gelonghui, May 9丨Chen Xin Pharmaceutical (603367.SH) said at the performance briefing that Chen Xin Pharmaceutical adheres to the development concept of “introducing innovation, honesty and trustworthiness” and has always used scientific and technological innovation as the driving force for sustainable development. In 2023, R&D investment accounted for more than 8% of revenue, which strongly supported the company's transformation, upgrading and sustainable development. At the same time, the company adheres to the combination of independent innovation and cooperative innovation. On the basis of independent research and development, the company attaches great importance to various collaborations. It has successively cooperated with Georgia State University in the United States, Liverpool University in the UK, Peking University, the Academy of Military Medical Sciences, China Pharmaceutical University, and Shandong
The actual controller of Chenxin Pharmaceutical (603367.SH) completed an increase of 1.8751 million shares
Chenxin Pharmaceutical (603367.SH) announced that Du Zhenxin, the actual controller, chairman and general manager of the company, has passed through Shanghai...
Cisen Pharmaceutical Names Chief Financial Officer
Cisen Pharmaceutical (SHA:603367) appointed one of its directors, Xu Xinbing, as chief financial officer, according to the company's filing on the Shanghai Stock Exchange. Xu will take over from Du Zh
Chenxin Pharmaceutical (603367.SH) announced its 2023 annual results, with net profit of 521 million yuan, an increase of 48.97% over the previous year
Chenxin Pharmaceutical (603367.SH) disclosed its 2023 annual report, and the company achieved 44 revenue in 2023...
Cisen Pharmaceutical's (SHSE:603367) Earnings Trajectory Could Turn Positive as the Stock Rises 6.9% This Past Week
For many, the main point of investing is to generate higher returns than the overall market. But in any portfolio, there will be mixed results between individual stocks. So we wouldn't blame long te
Chen Xin Pharmaceutical (603367.SH): Fodu Pharmaceutical plans to apply for listing on the Beijing Stock Exchange
Gelonghui, January 3, 丨 Chenxin Pharmaceutical (603367.SH) announced that the company held the 26th meeting of the 4th board of directors and the 25th meeting of the 4th board of supervisors on January 3, 2024. The meetings separately reviewed and passed the “Proposal on the Holding Subsidiary Shandong Chenxin Fodu Pharmaceutical Co., Ltd. to apply for listing on the Beijing Stock Exchange”. The board of directors agreed to the holding subsidiary Fodu Pharmaceutical planning to apply for listing on the Beijing Stock Exchange.
No Data